http://www.chemotherapyadvisor.com Latest articles from Chemotherapy Advisor Chemotherapy Advisor Home Chemotherapy treatment regimens, cancer news, clinical trials, feature stories, conference coverage, continuing medical education, supportive care, and additional resources to empower oncology healthcare professionals with practice-focused and comprehensive clinical and drug information that is reflective of current and emerging principles of care and optimizes patient outcomes. Home custserv@haymarketmedia.com no Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, according to a new study. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an abnormal physical examination or an abnormal blood test at the time of relapse, researchers say. http://www.chemotherapyadvisor.com/relapse-of-diffuse-large-b-cell-lymphoma-not-detected-by-imaging-scans/article/294835/ Fri, 24 May 2013 18:30:00 GMT Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, according to a new study. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an abnormal physical examination or an abnormal blood test at the time of relapse, researchers say. Chemotherapy Advisor Within 7 years of the World Trade Center attacks, police, firefighters, and others who worked at Ground Zero faced a higher risk of cancer. http://www.chemotherapyadvisor.com/increased-cancer-risk-found-in-911-world-trade-center-rescue-and-recovery-workers/article/294834/ Fri, 24 May 2013 17:00:00 GMT Within 7 years of the World Trade Center attacks, police, firefighters, and others who worked at Ground Zero faced a higher risk of cancer. Chemotherapy Advisor The FDA is allowing marketing of Roche's Tina-quant HbA1cDx assay, the first HbA1c test for the diagnosis of diabetes. http://www.chemotherapyadvisor.com/new-hba1c-test-fda-approved-to-diagnose-diabetes/article/294740/ Fri, 24 May 2013 13:45:59 GMT The FDA is allowing marketing of Roche's Tina-quant HbA1cDx assay, the first HbA1c test for the diagnosis of diabetes. Chemotherapy Advisor Patients at higher or lower risk for having their cancer recur elsewhere in the body more than 5 years after diagnosis can be differentiated by a gene expression test. The test measures the expression levels of 58 genes in estrogen receptor-positive breast cancers. These research results were presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. http://www.chemotherapyadvisor.com/late-recurrence-risk-in-breast-cancer-differentiated-by-gene-expression-test/article/294641/ Fri, 24 May 2013 13:00:00 GMT Patients at higher or lower risk for having their cancer recur elsewhere in the body more than 5 years after diagnosis can be differentiated by a gene expression test. The test measures the expression levels of 58 genes in estrogen receptor-positive breast cancers. These research results were presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. Chemotherapy Advisor FOLFIRINOX chemotherapy plus chemoradiation helped make resection possible in locally advanced pancreatic cancer. http://www.chemotherapyadvisor.com/locally-advanced-pancreatic-cancer-responds-to-folfirinox/article/294690/ Fri, 24 May 2013 11:00:00 GMT FOLFIRINOX chemotherapy plus chemoradiation helped make resection possible in locally advanced pancreatic cancer. Chemotherapy Advisor Upsher Smith announced the completion of its Phase 3 PREVAIL study for USL255 (extended-release topiramate) as an adjunctive treatment for epilepsy in patients with refractory partial-onset seizures. http://www.chemotherapyadvisor.com/extended-release-topiramate-shows-positive-treatment-effect-for-epilepsy/article/294483/ Wed, 22 May 2013 18:27:10 GMT Upsher Smith announced the completion of its Phase 3 PREVAIL study for USL255 (extended-release topiramate) as an adjunctive treatment for epilepsy in patients with refractory partial-onset seizures. Chemotherapy Advisor Salix announced the outcome and completion of two Phase 3 studies which evaluated the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis. http://www.chemotherapyadvisor.com/significant-results-for-budesonide-foam-in-ulcerative-proctitis-proctosigmoiditis/article/294389/ Wed, 22 May 2013 15:20:50 GMT Salix announced the outcome and completion of two Phase 3 studies which evaluated the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis. Chemotherapy Advisor Although further safety data is needed, endoscopic ultrasound may prove to be an effective way of administering localized chemotherapy. http://www.chemotherapyadvisor.com/endoscopic-ultrasound-an-innovative-way-to-administer-chemotherapy/article/294184/ Wed, 22 May 2013 10:00:00 GMT Although further safety data is needed, endoscopic ultrasound may prove to be an effective way of administering localized chemotherapy. Chemotherapy Advisor The FDA has approved Bayer's Xofigo for the treatment of advanced prostate cancer with bone metastases. http://www.chemotherapyadvisor.com/xofigo-approved-for-advanced-prostate-cancer-with-bone-metastases/article/293521/ Wed, 15 May 2013 15:59:59 GMT The FDA has approved Bayer's Xofigo for the treatment of advanced prostate cancer with bone metastases. Chemotherapy Advisor The cobas EGFR Mutation Test has been approved to identify patients with non-small cell lung cancer who are candidates for receiving Tarceva as first-line treatment. http://www.chemotherapyadvisor.com/fda-approves-egfr-mutation-test-for-lung-cancer-patients/article/293451/ Wed, 15 May 2013 15:37:41 GMT The cobas EGFR Mutation Test has been approved to identify patients with non-small cell lung cancer who are candidates for receiving Tarceva as first-line treatment. Chemotherapy Advisor The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. http://www.chemotherapyadvisor.com/fda-reviewing-adcetris-for-retreatment-and-extended-duration-therapy/article/293339/ Tue, 14 May 2013 15:32:16 GMT The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Chemotherapy Advisor Patients with cancer are living longer thanks to new cancer treatments; however, their financial well-being may suffer as a result. http://www.chemotherapyadvisor.com/innovative-cancer-treatments-increase-patients-financial-toxicity/article/294295/ Mon, 01 Jan 0001 05:00:00 GMT Patients with cancer are living longer thanks to new cancer treatments; however, their financial well-being may suffer as a result. Chemotherapy Advisor Advisory Board member Martin S. Tallman, MD, shares the unusual case of a patient with pancytopenia. http://www.chemotherapyadvisor.com/a-47-year-old-woman-with-pancytopenia-after-treatment-with-radioiodine-therapy/slideshow/966/ Mon, 01 Jan 0001 05:00:00 GMT Advisory Board member Martin S. Tallman, MD, shares the unusual case of a patient with pancytopenia. Chemotherapy Advisor Tara Morrison, MD, Advisory Board member, shares the case of a 66-year-old African American man with weight loss and pain around the abdomen. http://www.chemotherapyadvisor.com/a-rare-cause-of-intestinal-dysmotility-in-a-patient-with-small-cell-lung-cancer/slideshow/985/ Mon, 01 Jan 0001 05:00:00 GMT Tara Morrison, MD, Advisory Board member, shares the case of a 66-year-old African American man with weight loss and pain around the abdomen. Chemotherapy Advisor Review drug information for ZYTIGA® (abiraterone acetate) in a convenient slide-by-slide format. http://www.chemotherapyadvisor.com/zytiga-abiraterone-acetate/slideshow/1333/ Mon, 01 Jan 0001 05:00:00 GMT Review drug information for ZYTIGA® (abiraterone acetate) in a convenient slide-by-slide format. Chemotherapy Advisor Two recent studies demonstrate that microwave ablation offers rapid pain relief with few complications. http://www.chemotherapyadvisor.com/microwave-ablation-may-offer-pain-relief-for-patients-with-bone-tumors/article/293682/ Mon, 01 Jan 0001 05:00:00 GMT Two recent studies demonstrate that microwave ablation offers rapid pain relief with few complications. Chemotherapy Advisor Advanced, metastatic melanoma is an aggressive disease with a poor prognosis; but therapies targeting gene mutations may offer hope to some patients. http://www.chemotherapyadvisor.com/targeting-braf-mutation-in-melanoma-treatment/article/294566/ Mon, 01 Jan 0001 05:00:00 GMT Advanced, metastatic melanoma is an aggressive disease with a poor prognosis; but therapies targeting gene mutations may offer hope to some patients. Chemotherapy Advisor Radiation therapy can cause morbidity in patients with cancer, so trials of radiosensitizing agents that can target tumors and save healthy tissue are in development. http://www.chemotherapyadvisor.com/the-search-for-targeted-radiosensitizing-agents/article/293606/ Mon, 01 Jan 0001 05:00:00 GMT Radiation therapy can cause morbidity in patients with cancer, so trials of radiosensitizing agents that can target tumors and save healthy tissue are in development. Chemotherapy Advisor